ASX Announcement

FIRST HALF FY26 RESULTS RELEASE AND INVESTOR CALL

19 February 2026, Adelaide, Australia: Mayne Pharma Group Limited (Mayne Pharma) (ASX: MYX), announces that it will release its financial statements for the half year ended 31 December 2025 on Monday, 23 February 2026.

A webcast of the results will be held at 9.30am AEDT on Monday, 23 February 2026 (5.30pm Eastern US Time on Sunday, 22 February 2026).

Participants can register for the webcast by navigating to:
https://ccmediaframe.com/?id=C6LzkOZC

For further information contact:

Dr Tom Duthy
Investor Relations
+61 402 493 727
ir@maynepharma.com

Authorised for release to the ASX by the Board Chair

About Mayne Pharma

Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercialising novel pharmaceuticals, offering patients better, safe and more accessible medicines. Mayne Pharma is a leader in dermatology and women's health in the United States and also provides contract development and manufacturing services to clients worldwide. Mayne Pharma has a 40-year track record of innovation and success in developing new oral drug delivery systems. These technologies have been successfully commercialised in numerous products that continue to be marketed around the world. To learn more about Mayne Pharma, please visit maynepharma.com.